These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1902755)

  • 1. Fact and fiction--results of the cardiac arrhythmia suppression trial.
    Wyse DG
    Can J Cardiol; 1991; 7(1):51-4; discussion 55-8. PubMed ID: 1902755
    [No Abstract]   [Full Text] [Related]  

  • 2. The cardiac arrhythmia suppression trial (CAST).
    Ruskin JN
    N Engl J Med; 1989 Aug; 321(6):386-8. PubMed ID: 2501683
    [No Abstract]   [Full Text] [Related]  

  • 3. An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
    Coyle JD; Schaal SF
    DICP; 1989 Jun; 23(6):478-9. PubMed ID: 2500783
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons from the cardiac arrhythmia suppression trial.
    Garratt C; Ward DE; Camm AJ
    BMJ; 1989 Sep; 299(6703):805-6. PubMed ID: 2510839
    [No Abstract]   [Full Text] [Related]  

  • 5. Flecainide and CAST.
    Lancet; 1989 Aug; 2(8661):481-2. PubMed ID: 2570188
    [No Abstract]   [Full Text] [Related]  

  • 6. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for cardiac arrhythmias: new warning.
    Med Lett Drugs Ther; 1989 May; 31(792):48. PubMed ID: 2497313
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiarrhythmic therapy--conventional wisdom challenged.
    Turakhia DP
    J Assoc Physicians India; 1990 Aug; 38(8):605. PubMed ID: 2123185
    [No Abstract]   [Full Text] [Related]  

  • 9. Consequences of the Cardiac Arrhythmia Suppression Trial: calamity or clarity?
    Maloney JD
    Cleve Clin J Med; 1989 Sep; 56(6):649-53. PubMed ID: 2509109
    [No Abstract]   [Full Text] [Related]  

  • 10. CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1990 Mar; 11(3):194-9. PubMed ID: 2108031
    [No Abstract]   [Full Text] [Related]  

  • 11. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL; Wilkinson WE
    Am J Cardiol; 1991 May; 67(11):976-80. PubMed ID: 1902055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
    Bigger JT
    J Am Coll Cardiol; 1990 Jan; 15(1):243-5. PubMed ID: 2104884
    [No Abstract]   [Full Text] [Related]  

  • 16. Encainide and flecainide in children: separating the wheat from the chaff.
    Perry JC; Garson A
    J Am Coll Cardiol; 1991 Aug; 18(2):366-7. PubMed ID: 1906903
    [No Abstract]   [Full Text] [Related]  

  • 17. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
    Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP
    J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
    Hallstrom AP; Anderson JL; Carlson M; Davies R; Greene HL; Kammerling JM; Romhilt DW; Duff HJ; Huther M
    Am Heart J; 1995 Jul; 130(1):71-9. PubMed ID: 7611126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Akhtar M; Breithardt G; Camm AJ; Coumel P; Janse MJ; Lazzara R; Myerburg RJ; Schwartz PJ; Waldo AL; Wellens HJ
    Circulation; 1990 Mar; 81(3):1123-7. PubMed ID: 1689621
    [No Abstract]   [Full Text] [Related]  

  • 20. Late proarrhythmia and understanding the time of occurrence of proarrhythmia.
    Kennedy HL
    Am J Cardiol; 1990 Nov; 66(15):1139-43. PubMed ID: 2121018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.